FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006844370> ?p ?o ?g. }

• W3006844370 endingPage "694" @default.
• W3006844370 startingPage "684" @default.
• W3006844370 abstract "Most women with ovarian cancer experience disease relapse, presenting numerous treatment challenges for clinicians. Maintenance therapy in the relapsed setting aims to extend the time taken for a cancer to progress, thus delaying the need for additional treatments. Four therapies are currently approved in the USA for secondline maintenance treatment of platinum sensitive, recurrent ovarian cancer: one antivascular endothelial growth factor agent (bevacizumab) and three poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors (olaparib, niraparib, and rucaparib). In addition to efficacy, maintenance therapies must have a good tolerability profile and no significant detrimental impact on quality of life, as patients who receive maintenance are generally free from cancer related symptoms. Data from key bevacizumab trials (OCEANS, NCT00434642 ; GOG-0213, NCT00565851 ; MITO16B, NCT01802749 ) and PARP inhibitor trials (Study 19, NCT00753545 ; SOLO2, NCT01874353 ; NOVA, NCT01847274 ; ARIEL3, NCT01968213 ) indicate that bevacizumab and the PARP inhibitors are effective in patients with platinum sensitive, recurrent ovarian cancer but differ in their tolerability profiles. In addition, the efficacy of PARP inhibitors is dependent on the presence of homologous recombination repair deficiency, with patients with the deficiency experiencing greater responses from treatment compared with those who are homologous recombination repair proficient. Allowing for caveats of cross trial comparisons, we advise that clinicians account for the following points when choosing whether and when to administer a secondline maintenance treatment for a specific patient: presence of a homologous recombination repair deficient tumor; the patient’s baseline characteristics, such as platelet count and blood pressure; mode of administration of therapy; and consideration of future treatment options for thirdline and later therapy." @default.
• W3006844370 created "2020-03-06" @default.
• W3006844370 creator A5009234043 @default.
• W3006844370 creator A5026269100 @default.
• W3006844370 creator A5043625183 @default.
• W3006844370 date "2020-02-19" @default.
• W3006844370 modified "2023-10-03" @default.
• W3006844370 title "Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review" @default.
• W3006844370 cites W1484356204 @default.
• W3006844370 cites W1608269846 @default.
• W3006844370 cites W1793338775 @default.
• W3006844370 cites W1964736695 @default.
• W3006844370 cites W1965398601 @default.
• W3006844370 cites W2106157865 @default.
• W3006844370 cites W2110017381 @default.
• W3006844370 cites W2111437716 @default.
• W3006844370 cites W2118548073 @default.
• W3006844370 cites W2123696077 @default.
• W3006844370 cites W2130078242 @default.
• W3006844370 cites W2135525536 @default.
• W3006844370 cites W2147071985 @default.
• W3006844370 cites W2154885792 @default.
• W3006844370 cites W2160466424 @default.
• W3006844370 cites W2162645859 @default.
• W3006844370 cites W2171658624 @default.
• W3006844370 cites W2199466904 @default.
• W3006844370 cites W2519148856 @default.
• W3006844370 cites W2528228811 @default.
• W3006844370 cites W2550229146 @default.
• W3006844370 cites W2557666746 @default.
• W3006844370 cites W2560862072 @default.
• W3006844370 cites W2605456582 @default.
• W3006844370 cites W2611302285 @default.
• W3006844370 cites W2622898429 @default.
• W3006844370 cites W2737389832 @default.
• W3006844370 cites W2754327139 @default.
• W3006844370 cites W2772338061 @default.
• W3006844370 cites W2804717005 @default.
• W3006844370 cites W2810879504 @default.
• W3006844370 cites W2811216696 @default.
• W3006844370 cites W2883673963 @default.
• W3006844370 cites W2884001607 @default.
• W3006844370 cites W2885844784 @default.
• W3006844370 cites W2891245632 @default.
• W3006844370 cites W2896626889 @default.
• W3006844370 cites W2896628407 @default.
• W3006844370 cites W2897430921 @default.
• W3006844370 cites W2900631029 @default.
• W3006844370 cites W2935541805 @default.
• W3006844370 cites W2973408122 @default.
• W3006844370 cites W2976139792 @default.
• W3006844370 cites W4240685303 @default.
• W3006844370 cites W4248099135 @default.
• W3006844370 doi "https://doi.org/10.1136/ijgc-2019-001041" @default.
• W3006844370 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32079709" @default.
• W3006844370 hasPublicationYear "2020" @default.
• W3006844370 type Work @default.
• W3006844370 sameAs 3006844370 @default.
• W3006844370 citedByCount "6" @default.
• W3006844370 countsByYear W30068443702021 @default.
• W3006844370 countsByYear W30068443702022 @default.
• W3006844370 crossrefType "journal-article" @default.
• W3006844370 hasAuthorship W3006844370A5009234043 @default.
• W3006844370 hasAuthorship W3006844370A5026269100 @default.
• W3006844370 hasAuthorship W3006844370A5043625183 @default.
• W3006844370 hasConcept C104317684 @default.
• W3006844370 hasConcept C121608353 @default.
• W3006844370 hasConcept C126322002 @default.
• W3006844370 hasConcept C143998085 @default.
• W3006844370 hasConcept C182979987 @default.
• W3006844370 hasConcept C197934379 @default.
• W3006844370 hasConcept C2776694085 @default.
• W3006844370 hasConcept C2777802072 @default.
• W3006844370 hasConcept C2778283404 @default.
• W3006844370 hasConcept C2778375690 @default.
• W3006844370 hasConcept C2779138821 @default.
• W3006844370 hasConcept C2779962180 @default.
• W3006844370 hasConcept C2780427987 @default.
• W3006844370 hasConcept C54355233 @default.
• W3006844370 hasConcept C71924100 @default.
• W3006844370 hasConcept C82381507 @default.
• W3006844370 hasConcept C86803240 @default.
• W3006844370 hasConceptScore W3006844370C104317684 @default.
• W3006844370 hasConceptScore W3006844370C121608353 @default.
• W3006844370 hasConceptScore W3006844370C126322002 @default.
• W3006844370 hasConceptScore W3006844370C143998085 @default.
• W3006844370 hasConceptScore W3006844370C182979987 @default.
• W3006844370 hasConceptScore W3006844370C197934379 @default.
• W3006844370 hasConceptScore W3006844370C2776694085 @default.
• W3006844370 hasConceptScore W3006844370C2777802072 @default.
• W3006844370 hasConceptScore W3006844370C2778283404 @default.
• W3006844370 hasConceptScore W3006844370C2778375690 @default.
• W3006844370 hasConceptScore W3006844370C2779138821 @default.
• W3006844370 hasConceptScore W3006844370C2779962180 @default.
• W3006844370 hasConceptScore W3006844370C2780427987 @default.
• W3006844370 hasConceptScore W3006844370C54355233 @default.
• W3006844370 hasConceptScore W3006844370C71924100 @default.
• W3006844370 hasConceptScore W3006844370C82381507 @default.

• next